OMEICOS Therapeutics

0 followers


OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Headquarters

Berlin, Germany

Employees

11-50

Links

Org chart

Robert Fischer
Co-Founder, CEO & CSO

Robert Fischer

Collapse
Simon Russell
CBO, Consultancy
Karen Uhlmann
VP of Operations & IP, Co-Founder
Edita Bade
Head of Finance & Controlling
Anne Konkel
Klinischer Projektmanager
Janine Lossie
Clinical Project Manager